<span><span style="font-size: medium;"><strong><br />Galapagos NV</strong></span></span><span style="font-size: medium;"><strong><span> (OTC: GLPYY) & (Euronext: GLPG)<br /><br />Galapagos is specialized in novel modes-of-action, with a large pipeline of five Phase 2 (two led by GSK), one Phase 1, six pre- clinical, and more than 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications. <br /><br />The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta, has 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.</span></strong></span><br /><br /><span style="font-size: medium;"><strong>Company Website: <a rel="nofollow" href="http://www.glpg.com/" target="_blank">http://www.glpg.com/</a></strong></span>